ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
It is commonly held that financial buyers--banks and investment funds with mostly short-term gains in mind--have become an all-powerful force in the competition to buy and sell businesses. True, they are a factor, but in the chemical industry the scales are tipping in favor of strategic corporate buyers.
"People make a lot of noise about the importance of financial buyers in the market. They get a disproportionate share of attention," says Peter Young, president of Young & Partners--an investment banking firm that provides merger, acquisition, divestiture, and other services to chemical and life sciences firms.
According to Young, who recently shared his just-completed study on chemical industry financial trends with C&EN, financial buyers made five of the 10 largest chemical acquisitions in 2004. Strategic corporate buyers accounted for the balance. Overall, however, financial buyers were responsible for only a quarter of the 85 deals completed in 2004, down from 28% of 68 deals in 2003.
Based on value, financial buyers of chemical assets spent slightly more in 2004 than in the year earlier: $10.9 billion compared with $10.3 billion in 2003. But in the more dynamic market of 2004, financial buyers accounted for only 35% of the $31 billion in chemical merger and acquisition activity, versus 49% of the $21 billion in activity in 2003.
According to Young's statistics, Kohlberg Kravis Roberts (KKR), the majority shareholder in Rockwood Specialties, was behind the largest financially motivated chemical acquisition in 2004. Rockwood itself was created in 2000 when KKR bought several chemical operations from Laporte, prior to that company's acquisition by Degussa. Then last year KKR paid $2.7 billion to buy four Dynamit Nobel businesses and merge them with Rockwood.
Another financial buyer, Blackstone Group, led the charge to take the German firm Celanese private last April for $2.1 billion. Blackstone turned around and sold shares to the public in a new U.S.-based Celanese in February of this year.
Bain Capital engineered the $1.7 billion purchase of chemical distributor Brenntag. Clayton, Dubilier & Rice bought Merck KGaA's VWR laboratory supplies business for $1.7 billion, and Apollo Management bought Borden Chemical from KKR for $1.2 billion.
But while a financial buyer, Blackstone, engineered the largest acquisition in 2003--the $4.35 billion purchase of water services firm Ondeo Nalco--a corporate strategic buyer pulled off the biggest deal in 2004. In April, Koch Industries bought the Invista fibers business from DuPont for $4.2 billion.
Cargill and Air Liquide arranged the second and third largest combinations last year. Cargill Crop Nutrition got hitched with IMC Global to form the new fertilizer entity Mosaic in a $3.7 billion deal that closed in October. And Air Liquide purchased most of the industrial gases assets of Messer Griesheim for $3.2 billion in May.
Two other significant strategic acquisitions took place last year as well. In November, Lyondell Chemical completed the $2.6 billion purchase of Millennium Chemicals. In June, Lubrizol spent nearly $1.9 billion to buy specialty chemicals and materials maker Noveon from a group of financial investors that included AEA Investors, Credit Suisse First Boston, and MidOcean Capital Investors.
VENTURE CAPITAL
The Next Big Thing
Established businesses attract investment bankers, private equity funds, and strategic corporate buyers. Start-up businesses attract many of the same suitors. With small start-up companies, however, the risks of investing and losing it all are greater. But then, the potential rewards are greater, too.
And there is a lot of money chasing the next big thing. According to the National Venture Capital Association (NVCA), 170 venture-capital funds raised $17.6 billion in 2004, $7 billion more than in 2003.
NVCA predicts that venture capitalists will continue to look for investments in new technology in 2005. And just as in the recent past, much of the money raised will go to start-up software and life sciences businesses.
Among the most promising areas for investment, the group says, will be energy, clean technology, and financial services. Investors will closely watch emerging areas such as stem cell research and nanotechnology but aren't ready to put much money into them.
The life sciences sector, including biotechnology, is the largest single investment sector and accounted for 27% of all venture investments in 2004, NVCA says, with $5.6 billion placed in 568 companies. "Even with scientific advances of recent years, we are an aging population suffering from dozens of underserved diseases," says Jim Healy of Sofinnova Ventures. "Biotech is here to stay."
FINANCIAL BUYERS have been especially active since 2000 when they were involved in 16 chemical deals, up from six in 1999. Overnight, it seems, they went from participating in fewer than 10% of all chemical acquisitions to 20% or more of all such deals from 2000 to 2004.
At a New York City meeting in December of the American Section of the Socit de Chemie Industrielle, Young said, "The challenge for financial buyers is getting their money out of the deal." Over the past five years, only a few have successfully sold out and made a profit, such as AEA's group, which sold Noveon; Ripplewood, which sold Kraton Polymers to another group of investors; and Apollo, which completed a public offering of Compass Minerals.
Some financial deals have ended in failure, Young said. Financial buyers owned Penn Specialties and Geo Specialty Chemicals when they declared bankruptcy in recent years. A financial buyer owned Vantico when it got into financial difficulties, was bought by MatlinPatterson Global Opportunities, and merged into Huntsman.
Financial buyers typically look for a way out and a profit within five to seven years of initial purchase, Young said. By that measure, of the 89 financial deals completed since 2000, a good many are approaching their ideal exit dates. "Financial buyers are generally unhappy if they haven't sold a business within five years of purchase."
Private equity investor interest in the chemical industry is a relatively recent phenomenon. "Twenty years ago, business auctions were rare and private equity wasn't available," says Kumar Shah, who was senior vice president of corporate business development at Noveon until it was sold to Lubrizol. He is now a senior adviser for chemicals with Bear Stearns Merchant Banking. Today, about two-thirds of businesses put on the market are auctioned to the highest bidder. And private equity money is available because "financing is cheap," says Shah.
According to market research firm Dealogic, private equity firms accounted for just 9% of global merger and acquisition activity last year in all industries, based on the number of completed deals. Such firms accounted for about 14% of activity based on dollar volume. Comparing these figures to Young's data shows that financial buyers have an inordinate interest in chemical operations.
Shah, who also worked to buy and sell businesses at Cytec Industries and American Cyanamid, explains why. Private equity funds are particularly interested in chemical businesses that are "stable, mature, and durable." They are attracted to specialty chemical firms because such businesses "tend to be less cyclical, and the customer base won't change overnight." Once they own a business, private equity buyers will look to reduce fixed costs and improve profitability before they sell to another buyer or offer shares to the public, Shah notes.
BETWEEN 2000 and 2003, financial buyers did relatively well because corporate earnings were poor. Chemical companies were particularly cash-strapped as they dealt with overcapacity, weak demand, and raw material cost pressures. As the economy picked up in 2004--and along with it chemical industry profits--"industrial buyers have become more assertive," Young says.
"Industrial buyers have done a lot of cleanup," he says. "They are in better shape now than they were a year ago. They've put out most of the local fires and feel more confident about their business, and they are willing to venture out into the market."
That doesn't mean financial buyers are going to go away, Young adds. Right now, private equity firms have "easy access to bank debt, the high-yield market is strong, and interest rates are low."
Young expects the number of acquisitions to continue at a high level for at least another year. Major drivers, he says, will be ongoing industrial restructuring, business portfolio rearrangements, consolidation activity, and active financial buyers.
Several chemical transactions that have already closed this year, or that have been announced and will close soon, should drive the value of deals in 2005 beyond the $31 billion total in 2004.
They include Cargill's purchase of Dow Chemical's half interest in a polylactic acid joint venture, Cytec Industries' $1.8 billion purchase of UCB's surface specialties business, and Henkel's $575 million purchase of Sovereign Specialty Chemicals. They also include Danisco's $419 million purchase of Eastman Chemical's stake in Genencor and Borden Chemical's purchase of Bakelite. In addition, PQ Corp. has put itself up for sale, and Akzo Nobel plans to sell six chemical businesses with annual sales of nearly $1 billion.
According to Young, "The increased aggressiveness of industrial buyers has lowered and will continue to lower the relative market clout of financial buyers." But those financial buyers, he asserts, will help keep the numbers up by "absorbing deals that would otherwise fail."
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter